ALLO-605

anti-BCMA allogeneic CAR T cell therapy · Allogene Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALLO-605, covering 2024-06-28 to 2024-06-28. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

See pricing